NGM·Healthcare·$1.4B·#483 / 520 in Healthcare
CRVS Corvus Pharmaceuticals, Inc.
19CRITICAL
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY35
VALUATION50
GOVERNANCE21
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
N/A
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
2 months
3
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
1.5%
99
< 25% strong
Price / Sales
Market cap relative to trailing revenue
N/A
50
< 3x strong
Rule of 40
Growth rate plus operating margin
N/A
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
3.5%
28
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+23.4%
7
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE CRVS WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when CRVS's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.